Core Insights - Nicox SA presented positive Phase 3 data for NCX 470 at the 2026 American Glaucoma Society Annual Meeting, highlighting its potential as a new treatment for glaucoma [1][3] - NCX 470 demonstrated a best-in-class intraocular pressure (IOP) lowering efficacy of up to 10mmHg from baseline, meeting the efficacy requirements for New Drug Applications in the U.S. and China [2][3] Company Overview - Nicox SA is an international ophthalmology company focused on developing innovative solutions for vision maintenance and ocular health [8] - The lead product, NCX 470, is a nitric oxide-donating bimatoprost eye drop aimed at lowering IOP in patients with open-angle glaucoma or ocular hypertension [8] Clinical Trial Results - The DENALI Trial showed that NCX 470 0.1% was non-inferior to latanoprost 0.005% at all time points, with NCX 470 achieving statistically superior IOP reductions at 3 out of 6 evaluated time points [4][7] - NCX 470 was found to be safe and well tolerated, with low discontinuation rates and no serious adverse events reported [5][7] Mechanism of Action - NCX 470 operates through a dual mechanism of action, enhancing both trabecular meshwork and uveoscleral outflow to lower IOP [3][6] - Preclinical data suggest potential benefits in retinal protection, further differentiating NCX 470 from existing treatments [3] Market Potential - Approximately 40% of glaucoma patients do not reach their target IOP with current monotherapies, indicating a significant need for new treatment options [3] - Nicox's strategic partnerships for NCX 470 include licensing agreements with Ocumension Therapeutics and Kowa for various markets [8]